Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected...

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Recombinant canarypox virus (ALVAC) vectors are explored for cancer immunotherapy.
• Melanoma-associated antigen Melan-A/MART-1 is a target for cancer vaccines.
• Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating immune responses.

Purpose of the Study:

• To evaluate the efficacy of ALVAC encoding Melan-A/MART-1 antigen in a dendritic cell (DC)-based cancer immunotherapy strategy.
• To investigate the antigen processing and presentation capabilities of ALVAC-infected DCs.
• To assess the induction of tumor antigen-specific T cell responses.

Main Methods:

• Infection of DCs with ALVAC encoding Melan-A/MART-1.
• Co-culture of infected and uninfected DCs to study cross-presentation.
• Flow cytometry, image cytometry, and confocal microscopy for antigen uptake verification.
• In vitro functional assays including T cell clone stimulation, IFN-gamma production, HLA class I/peptide tetramer binding, ELISPOT, and cytotoxicity tests.

Main Results:

• ALVAC-infected DCs successfully expressed, processed, and presented Melan-A/MART-1 antigen.
• Cross-presentation of tumor antigen was observed when uninfected DCs were co-cultured with ALVAC-infected DCs, confirmed by uptake of apoptotic infected cells.
• A 2- to 3-fold increase in IFN-gamma production by a MART-1-specific T cell clone was noted.
• Induction of MART-1-specific T cell immune responses was confirmed through multiple immunological assays.

Conclusions:

• DCs infected with recombinant canarypox virus (ALVAC) serve as an effective platform for presenting tumor antigens.
• This DC-based approach can elicit robust tumor antigen-specific T cell immunity.
• The findings support the potential clinical application of this strategy in cancer immunotherapy.